Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the safety, tolerability, dose-limiting
toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once
daily, to patients with advanced solid tumours.
The secondary objectives of this study were:
- To determine pharmacokinetic parameters for CHR-2797 when administered orally at
increasing dose levels;
- To investigate the pharmacodynamic effects of CHR-2797 in blood mononuclear cells and,
when possible, tumour cells; - To enable a preliminary assessment of anti-tumour
activity of CHR-2797.